In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials (PDQ®)

Page Options

  • Print This Page
  • Email This Document
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
LiveHelp online chat

Clinical Trials (PDQ®)

Lung Cancer Biomarkers and Screening

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
No phase specifiedBiomarker/Laboratory analysis, Diagnostic, ScreeningActiveOver 50OtherCDR0000456198
NYU-H-8896-06-B, NCT00301119

Trial Description

Summary

RATIONALE: Screening tests that use biomarkers may help doctors find tumor cells early and plan effective treatment for lung cancer.

PURPOSE: This clinical trial is studying biomarkers in screening participants for lung cancer.

Further Study Information

OBJECTIVES:

  • Identify and validate biomarkers for the early detection of lung cancer in individuals at low- or high-risk for smoking-related cancers.
  • Identify preneoplastic cellular changes and lesions in these patients.

OUTLINE: Participants are stratified according to lung cancer risk status (with or without increased risk).

Group 1 (screening cohort): Participants complete a questionnaire and undergo pulmonary function testing, multidetector chest CT scan, sputum induction, and phlebotomy.

Group 2 (rule-out lung cancer): Participants complete the same questionnaire and undergo the same tests and scans as in group 1. Some participants may undergo fiberoptic bronchoscopy based upon CT scan results with transbronchial or endobronchial biopsies. Some participants may undergo lung resection. Tissue samples are collected from surgery or biopsy.

PROJECTED ACCRUAL: A total of participants will be accrued for this study.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Screening Cohort
  • At high- or low-risk for lung cancer
  • Smoking history ≥ 20 pack years*
  • With or without workplace exposure to asbestos
  • NOTE: * Participants with < 20 pack years of smoking are eligible if 50 years of age or older
  • Rule-Out Lung cancer group
  • Referred for evaluation of suspicious nodules with 1 of the following diagnoses:
  • Lung cancer
  • Nonmalignant nodules (control group)

PATIENT CHARACTERISTICS:

  • Not pregnant
  • No prior malignancy except nonmelanoma skin cancer

PRIOR CONCURRENT THERAPY:

  • Not specified

Trial Contact Information

Trial Lead Organizations/Sponsors

NYU Cancer Institute at New York University Medical Center

William N. RomPrincipal Investigator

William N Rom, MD, MPHPh: 212-263-6479
  Email: william.rom@nyumc.org

Trial Sites

U.S.A.
New York
  New York
 NYU Cancer Institute at New York University Medical Center
 William N. Rom, MD, MPH Ph: 212-263-6479
  Email: william.rom@med.nyu.edu

See All Trial Sites

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT00301119
ClinicalTrials.gov processed this data on July 14, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top